Skip to main content

Table 4 Drug resistance mutations present in each EQA panel

From: The Brazilian Network for HIV-1 Genotyping External Quality Control Assurance Programme

 

VL1

VL2

 

PROTEASE

REVERSE TRANSCRIPTASE

PROTEASE

REVERSE TRANSCRIPTASE

EQA1

WT

WT

L10V, M36M/I

WT

EQA2

V77I

M184V, T215Y, K103N, A98G, P225H

I54V, L63P, A71V, V82A, L90M

WT

EQA3

L10F, K20R, L33F, I54L, V82A

Y181C, R211K, T215C

L10V, L63P, V77I

M41L, M184V, Y188L, L210W, T215Y

EQA4

L10F, L63P, V77I, I84V, I93L

D67N, K70R, M184V, T215T/I, K219E

K20T, M46I, L63P, A71T, N88G

M41L, K103N, V118I, M184V, T215Y

EQA5

E35D, I62V, V71T, I84I, L90L/M

K103N, M184M, R221K, L214F, T215L

E35D, I62V, A71T, I84I, L90L/M

K103N, M184M, R211K, L214F, T215L

  1. (VL1 = viral load 1 of 2000 copies/mL and VL2 = 10,000 copies/mL. WT = wild type virus. A total of five codons at the protease and five codons at reverse transcriptase were selected for analysis. In the absence of drug resistance mutations, randomly selected wild type codons were chosen for the correct interpretation of mutations analysis. In case of ambiguities - mixed viruses population, i.e, M36M/I - we scored as correct only labs that reported the presence of both amino acids.)
Back to article page

Journal of the International AIDS Society

ISSN: 1758-2652